References
- Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, . In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839–45.
- Shinabarger DL. Mechanism of action of the oxazolidinone antibacterial agent. Expert Opin Investig Drugs 1999;8: 1195–202.
- Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR. In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 1999;43:2059–62.
- Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998;129:862–9.
- Ostabal MI, Suárez Pinilla MA, Sanz Sebastián C, Millastre A. Epidemiological study of nosocomial meningitis in neurological patients. Rev Neurol 1996;24:265–7.
- Villani P, Regazzi MB, Marubbi F, Viale P, Pagani L, Cristini F, . Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002;46:936–7.
- Beer R, Engelhardt KW, Pfausler B, Broessner G, Helbok R, Lackner P, . Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother 2007;51:379–82.
- Majcher-Peszynska J, Haase G, Sass M, Mundkowski R, Pietsch A, Klammt S, . Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. Eur J Clin Pharmacol 2008;64:1093–100.
- Abe S, Chiba K, Cirincione B, Grasela TH, Ito K, Suwa T. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol 2009;49:1071–8.
- Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986;11:257–82.
- Pfausler B, Spiss H, Beer R, Kampl A, Engelhardt K, Schober M, Schmutzhard E. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg 2003;98:1040–4.
- Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003;42:1129–40.
- Heinze A, Holzgrabe U. Determination of the extent of protein binding of antibiotics by means of an automated continuous ultrafiltration method. Int J Pharm 2006;311:108–12.
- MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003;51(Suppl 2):ii17–25.
- Slatter JG, Adams LA, Bush EC, Chiba K, Daley-Yates PT, Feenstra KL, . Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 2002;32:907–24.
- Milhorat TH. The third circulation revisited. J Neurosurg 1975;42:628–45.
- Shaikh ZH, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 2001;33:375–9.